Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...

Add-on oral antihistamines or montelukast (Singulair) do not add much benefit. In three separate trials, researchers randomized 3398 adolescent and adult patients with moderate-to-severe SAR ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

Journalist Annie Lowrey has a rare disease that causes a near-constant itch that doesn't respond to most treatments. She ...

It is further common practice to combine oral corticosteroids with antihistamines in the treatment of acute exacerbations of allergic rhinitis. The aim of this study was to investigate the effect ...

Acute and chronic conditions typically differ in how they develop and how long they last. Broadly speaking, acute conditions occur suddenly, have immediate or rapidly developing symptoms, and are ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good day, and welcome to the ARS Pharmaceuticals Third Quarter ...

Phenylephrine is included in many cold and flu products, but a scientific panel last year found that it doesn't really do its ...

A New York woman, who was inspired to become a living donor, met the young boy she helped save at the Cleveland Clinic over ...